2024-512756-38-00已完成2 期
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 27
- 主要终点
- Absolute change from baseline in Simple Endoscopic Score for Crohn's disease (SES-CD) at week 12.
研究概览
简要总结
The main objectives of this trial are to investigate a first signal of efficacy, safety and tolerability of BI 706321 in combination with ustekinumab treatment compared to placebo with ustekinumab treatment in patients with moderately to severely active CD at 12 weeks.
The primary objective is to estimate the difference in change from baseline in Simple Endoscopic Score for Crohn's disease (SES-CD) after 12 weeks. The primary treatment comparison will be between treatment groups while on treatment during the 12 week induction period.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of CD for at least 3 months prior to visit 1, as confirmed at any time in the past by endoscopy and/OR radiology, and supported by histology.
- •Elevated CRP (≥ 5 mg/L) OR elevated fecal calprotectin (≥ 250 μg/g)
- •Symptomatic CD defined as ≥ CDAI 150
- •Presence of mucosal ulcers in at least one segment of the ileum or colon and a SESCD score ≥ 7 (for patients with isolated ileitis ≥4)
- •Patients who are experienced to at least 1 tumor necrosis factor (TNF) antagonist at a dose approved for CD. Patients may have stopped TNF antagonist treatment due to primary or secondary non -responsiveness, intolerance, or for other reasons.
- •May be receiving a therapeutic dose of the following: Oral 5-ASA compounds Oral corticosteroids AZA, MP, 6-TG, or MTX
- •Women of childbearing potential (WOCBP)1 must be ready and able to use highly effective methods of birth control
- •Further inclusion criteria apply.
排除标准
- •Have any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to randomization and are not anticipated to require surgery. Patients with active fistulas may be included if there is no anticipation of a need for surgery and there are currently no abscesses present based on investigator`s judgement
- •Presence of clinically significant acute or chronic infections not otherwise listed, including viral hepatitis, COVID-19, or others based on investigator's judgement.
- •A marked baseline prolongation of QT/QTc interval (such as QTcF intervals that are greater than 450 ms for men, 470 ms for female) or any other relevant ECG finding at screening. Both have to be confirmed by repeated ECG recording.
- •Further exclusion criteria apply
- •Have complications of CD such as strictures, stenosis, short bowel syndrome, or any other manifestation that might require surgery, or could preclude the use of SESCD/ CDAI to assess response to therapy, or would possibly confound the evaluation of benefit from treatment with BI 706321
- •Patient with an IBD diagnosis other than CD
- •Have had any kind of bowel resection or diversion within 4 months or any other intraabdominal surgery within 3 months prior to visit
- •Patients with current ileostomy, colostomy, or ileorectal anastomosis are excluded.
- •Treatment with: - any non-biologic medication for IBD (tacrolimus or mycophenolate mofetil, systemic corticosteroids), other than those allowed per inclusion criteria, within 30 days prior to randomization - any biologic treatment with a TNF-alpha antagonist (adalimumab, infliximab, golimumab, certolizumab pegol) or vedolizumab (or a biosimilar) within 4 weeks prior to randomization. - any previous treatment with ustekinumab (or a biosimilar of this drug) - any previous treatment with an investigational (or subsequently approved) non-biologic/biologic drug for CD (including but not limited to JAK inhibitors [e.g. upadacitinib], S1P modulators, IL-23 inhibitors [e.g. risankizumab], antiintegrins). - any investigational drug for an indication other than CD during the course of the actual study and within 30 days or 5 half-lives (whichever is longer) prior to randomisation. - any prior exposure to rituximab within 1 year prior to randomisation.
- •Positive stool examination for C difficile (toxin A/B and GDH ag – test positive) or other intestinal pathogens <30 days prior to randomization.
- •Evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed
- •Increased risk of infectious complications (e.g. recent pyogenic inf, any congenital or acquired immunodeficiency (e.g. Human immunodeficiency virus), past organ or stem cell transplantation (with exception of a corneal transplant > 12 weeks prior to screening) or have ever received stem cell therapy (e.g., Prochymal). Prior treatment with a somatic cell therapy product (e.g., Alofisel) is not excluded, provided it was administered > 8 w prior to randomization BCG vaccines ≤ 1 year prior to randomization
- •Live or attenuated vaccination within 4 weeks prior to randomization
结局指标
主要结局
Absolute change from baseline in Simple Endoscopic Score for Crohn's disease (SES-CD) at week 12.
Absolute change from baseline in Simple Endoscopic Score for Crohn's disease (SES-CD) at week 12.
次要结局
- Percent change in SES-CD from baseline at Week 12-
- Endoscopic response (defined as ≥50% SES-CD reduction from baseline) or for a induction baseline SES-CD of 4, at least a 2 point reduction from induction baseline) at Week 12
- Endoscopic response (defined as ≥50% SES-CD reduction from baseline), or for a induction baseline SES-CD of 4, at least a 2 point reduction from induction baseline) at Week 48
- Endoscopic remission (defined as SES-CD score of ≤2) at week 12
- Endoscopic remission (defined as SES-CD score of ≤2) at week 48
- Biological remission, defined as C-reactive protein (CRP) <5 mg/L and faecal calprotectin (FCP) < 250 ug/g at week 12
- Biological remission, defined as CRP < 5 mg/L and FCP <250 ug/g at week 48
- Clinical remission at week 12, defined as a Crohn's Disease Activity Index (CDAI) score of <150
- Clinical remission at week 48, defined as a CDAI score of<150
- Clinical response at week 12, defined by a CDAI reduction from baseline of at least 100 points, or a CDAI score of <150
- Number of patients with treatment-emergent adverse event (TEAE) through end of treatment (EoT) and the residual effect period (REP) (i.e. through Visit 9)
研究者
CT disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (27)
Loading locations...
相似试验
已完成
1 期
A Study of HS-10518 in Healthy Adult Premenopausal Females in ChinaNCT07264192West China Second University Hospital60
已完成
1 期
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult VolunteersNCT07279636AlphaMol Science Ltd. (Shanghai)55
已完成
1 期
A single-centre, open-label, phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers2024-515124-36-00Integrative Research Laboratories Sweden AB12
招募中
1 期
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult ParticipantsNCT07262281Newsoara Biopharma Co., Ltd.74
招募中
1 期
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid TumorsCancerNCT07269899Sun Yat-sen University12